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Abstract
Background: Retrospective studies indicate associations between TSER (thymidylate synthase enhancer region) genotypes
and clinical outcomes in patients receiving 5-FU based chemotherapy, but well-controlled prospective validation has been
lacking.
Methods: In this phase II study (NCT00515216 registered through ClinicalTrials.gov, http://clinicaltrials.gov/show/
NCT00515216), patients with ‘‘good risk’’ TSER genotypes (at least one TSER*2 allele) were treated with FOLFOX
chemotherapy to determine whether prospective patient selection can improve overall response rates (ORR) in patients
with gastric and gastroesophageal junction (GEJ) cancers, compared with historical outcomes in unselected patients
(estimated 43%).
Results: The ORR in genotype-selected patients was 39.1% (9 partial responses out of 23 evaluable patients, 95% CI, 22.2 to
59.2), not achieving the primary objective of improving ORR. An encouraging disease control rate (DCR, consisting of partial
responses and stable diseases) of 95.7% was noted and patients with homozygous TSER*2 genotype showed better tumor
response.
Conclusions: In this first prospective, multi-institutional study in patients with gastric or GEJ cancers, selecting patients with
at least one TSER*2 allele did not improve the ORR but led to an encouraging DCR. Further studies are needed to investigate
the utility of selecting patients homozygous for the TSER*2 allele and additional genomic markers in improving clinical
outcomes for patients with gastric and GEJ cancers.
Trial Registration: ClinicalTrials.gov NCT00515216
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optimal therapy, the median survival in these patients is less than 1
year and survival at 5 years is essentially zero [2,3]. Recent
advances in our capacity to detect and target specific molecular
lesions in cancer cells and to obtain genetic information from
tumor tissues and patients allow for selection of optimal therapies,
improving the outcomes for these aggressive cancers. For example,
targeting HER-2 expressing gastroesophageal tumors with trastu-

Introduction
Cancers of the gastric cardia, gastroesophageal junction (GEJ)
and distal esophagus have been rapidly increasing in incidence in
the past decades, especially in patients younger than 40 years of
age [1]. Unfortunately, 80–90% of newly diagnosed patients
present with regional or distant metastatic disease and even with
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Checklist S1 and Protocol S1. The trial started (first patient
enrolled) in June 2008 and ended (last patient completed the
clinical study) in October 2010.

zumab led to an improvement in the survival of patients with
advanced disease [4]. However, for the majority of patients
selection of initial therapy remains largely empiric as most of the
regimens have similar response rates and median survival [3,5].
Thus, there is a clear need for approaches that can guide
treatment selection for the most effective regimens.
5-fluorouracil (5-FU) is one of the most commonly prescribed
chemotherapy agents. It has demonstrated preclinical synergy with
oxaliplatin in a variety of tumor types and this combination has
demonstrated clear efficacy in treating patients with gastric and
GEJ cancers [6–8]. Thymidylate synthase (TS, encoded by the
TYMS gene) is the critical enzyme in DNA synthesis and repair
and it is the primary target for 5-FU and other folate-based
antimetabolites [9]. Overexpression of TS has been linked to
clinical resistance to TS-targeted agents including 5-FU [10]. In
turn, genetic polymorphisms involving the promoter region of the
TYMS gene, specifically, the number of tandem repeat sequences
in the TS enhancer region (TSER - the 28-nucleotide G/C-rich
sequence in the 59-untranslated region) have been shown to be
important determinants of tumoral TS expression [11–15]. The
two most common TSER alleles are the two tandem repeats
(TSER*2, allelic frequency = 0.2,0.4) and the three tandem
repeats (TSER*3, allelic frequency = 0.6,0.8) [15].
Retrospective studies in colorectal cancer have demonstrated
that individuals with TSER*3/*3 genotype had a significantly
lower response rate and poorer outcomes to 5-FU compared with
those with at least one TSER*2 allele [11,16–18]. Additional
retrospective analyses of TS expression or TSER genotypes in
relation to clinical outcomes in patients with gastric cancers
replicated these findings [19,20]. More recently, findings from the
first prospective study evaluating the utility of TSER genotypes in
directing neoadjuvant chemoradiation for patients with rectal
carcinoma demonstrated that patients treated with 5-FU-based
chemoradiotherapy according to their TSER genotypes had
improved tumor downstaging [21]. Together, these studies
provide ample evidence that TS expression status and/or TSER
genotyping may be useful in selecting patients who are likely to
respond to treatment with 5-FU or its analogues.
This Phase II study was designed to prospectively select patients
with ‘‘good risk’’ TSER genotypes (i.e. TSER*2/*2 or *2/*3) and
treat them with a standard 5-FU-based regimen (FOLFOX; 5-FU,
leucovorin, oxaliplatin) in order to improve clinical outcomes in
patients with gastric and GEJ cancers. The primary end point of
this study was to determine whether TSER genotype-directed
chemotherapy would result in an improved overall response rate
(ORR, 60% or higher) compared to historical control response
rates in non-genotype selected patients (estimated 43%). The
secondary end points were to retrospectively assess whether other
genetic variations, in particular, additional polymorphic loci in the
TYMS gene and other genes involved in the disposition and
response to the FOLFOX regimen would influence the response in
the treated patients.

Eligibility
Adult ($18 years) patients who had histologically or cytologically confirmed adenocarcinoma of the stomach or GEJ and had
received no prior therapy for metastatic disease were eligible.
Subjects could have received prior neoadjuvant or adjuvant
therapy as long as the disease-free interval was longer than 6
months. Eligible patients had Eastern Cooperative Oncology
Group (ECOG) performance status #2, adequate organ and bone
marrow function, and an ability to understand and willingness to
sign written informed consent. Patients with known active brain
metastases, HIV on anti-retroviral therapy or other uncontrolled
intercurrent illnesses were excluded.

Study Design and Treatment
This was an open-label, non-randomized, investigator-initiated
multi-center study involving prospective genotyping (study flow
chart shown in Figure 1). Potentially eligible patients underwent a
blood draw for TSER genotyping. Patients with TSER*3/*3
genotype were not included in study treatment. Patients with
TSER*2/*2 or TSER*2/*3 genotypes received the modified
FOLFOX-6 treatment consisting of oxaliplatin 85 mg/m2 and
leucovorin 400 mg/m2 given over 2 hours along with 5-FU
400 mg/m2 given as an intravenous push over 5 minutes, followed
by 5-FU 2,400 mg/m2 given as an intravenous infusion of 46
hours. This treatment was repeated every 2 weeks in the absence
of unacceptable adverse events or disease progression.

Assessment of Efficacy and Toxicity
The patients were reevaluated for response every 8 weeks. In
addition to a baseline scan, confirmatory scans were performed
not less than 4 weeks following initial documentation of objective
response. Tumor response and progression were evaluated using
Response Evaluation Criteria in Solid Tumors (RECIST). Partial

Materials and Methods
Ethics Statement
The trial was done in accordance with the Declaration of
Helsinki and ICH Good Clinical Practice. The study protocol was
approved by the Vanderbilt University and Washington University Institutional Review Boards and all participants provided their
written informed consent to participate in this study. The study
was
registered
through
ClinicalTrials.gov
(Identifier:
NCT00515216). The protocol for this trial and supporting
TREND checklist are available as supporting information; see
PLOS ONE | www.plosone.org

Figure 1. A schematic diagram of the current phase II study
design.
doi:10.1371/journal.pone.0107424.g001
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(63.4%) had good risk genotypes (TSER*2/*2 or *2/*3) and
enrolled onto the trial. One patient with a good risk genotype
withdrew consent and was not treated on study. The majority of
patients had gastric cancer (73%) and good performance status
(69% ECOG PS of 1 or better). The median age of the
participants was 56 years and a majority (62%) was male.

response (PR) was defined as at least 30% decrease in the sum of
the longest diameter (LD) of target lesions, taking as reference the
baseline sum LD. Progressive disease (PD) was defined as at least a
20% increase in the sum of the LD of target lesions, taking as
reference the smallest sum LD recorded since the treatment
started or the appearance of one or more new lesions. Stable
disease (SD) was defined as neither sufficient shrinkage to qualify
for PR nor sufficient increase to qualify for PD. Toxicities were
graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI-CTCAE), version
3.0. Dose modifications were made depending on the type and
severity of toxicities observed.

Treatment and toxicities
Twenty five patients received at least one dose of study
treatment with the modified FOLFOX-6 regimen. A total of
128 cycles were administered, with a median of 5.5 cycles per
patient (range, 0.5–15 cycles). The occurrence and the incidence
of the main toxicities are reported in Table 2. The toxicities
experienced by the study participants were within the expected
range for patients receiving treatment with FOLFOX. The most
common toxicities were hematologic with grade 3 and 4
neutropenia, leukopenia and anemia recorded in 8 out of 25
(32%), 4 out of 25 (16%), and one out of 25 (4%) patients,
respectively. Only two out of 25 patients experienced grade 3
gastrointestinal toxicity and no participants had grade 4 gastrointestinal toxicity. Neurotoxicity was common and was observed in
44% (grade 1 in 20%, grade 2 in 16% and grade 3 in 8%) of the
patients. Fatigue was also common and was observed in 52%
(grade 1 in 40%, grade 2 in 4% and grade 3 in 8%) of the patients.
No treatment-related deaths were reported.

Retrospective Genotyping Analyses
Retrospective genotyping analyses by restriction fragment
length polymorphism (RFLP) were performed for two additional
loci in the TYMS gene (G.C SNP within the second 28-bp
tandem repeat of the 3R allele, rs34743033; 1494delTTAAAG in
the 39-UTR, rs34489327) and five loci in additional genes
reported to be associated with response and toxicity to the
FOLFOX regimen (ERCC1, c.354C.T, rs11615; ERCC2,
c.2251A.C, rs13181; GSTP1, c.313A.G, rs1695; XRCC1,
c.1196G.A, rs25487; and MDR1, c.3435C.T, rs1045642).
Briefly, regions encompassing the respective polymorphisms were
PCR amplified (Platinum PCR Supermix, Invitrogen) and
subjected to restriction enzyme digest to yield the diagnostic
fragmentation patterns (detailed conditions provided in Table S1
in File S1) [13,22–30]. The digested and undigested products from
each patient sample were visualized on 3% agarose gel along with
positive controls whose genotypes were verified by direct
sequencing.

Response to FOLFOX regimen, recurrence and survival
and TSER genotypes
Response to the modified FOLFOX-6 regimen in the 23
evaluable patients is shown in Table 3. Nine patients experienced
PR and no patient experienced complete response (CR), making
the overall response rate (CR+PR) to be 39.1% (95% confidence
interval (CI, Wilson), 22.2 to 59.2). When tumor responses are
compared between the two TSER genotype groups, patients with
the TSER*2/*2 genotype experienced a greater frequency of PR
and a less frequency of SD compared to those with the TSER*2/
*3 genotype (p = 0.02, Fisher’s exact test, Table 3). On the other
hand, only one out of 23 patients experienced PD, for an observed
disease control rate (CR+PR+SD) of 95.7% (95% CI, 79.0 to
99.2). OS and PFS plots for the enrolled patients are shown in
Figure 2. Median values for OS and PFS were 11.4 months (95%
CI, 6.3 to 16.3) and 6.2 months (95% CI, 5.2 to 8.6), respectively.
For both OS and PFS, patients with the TSER*2/*2 genotype had
a trend towards an improvement in median OS and PFS in
comparison to those patients with the TSER*2/*3 genotype
(Figure 3, OS, 20.9 vs 11.4 months; PFS, 10.2 vs 6.0 months).

Statistical Analyses
The primary objective of this study was to test whether selection
of patients according to TSER genotypes would improve
treatment response rates compared to the response rates previously
reported in an unselected population. Sample size estimation was
based on the assumed response rate of 43% with this regimen in
an unselected population and improving the response rate to a
minimum of 60% based on the retrospective data [19,20]. An
Optimum MinMax two-stage accrual design was employed [31].
In the initial step, 45 eligible patients were to be entered into the
study, with a final accrual goal of 75 if $20 responses were
observed in the first group. This design provides 90% statistical
power to detect a difference of 17% with a two-sided significance
level of ,0.05. Unfortunately, the current study had to be
terminated earlier than the initial stopping point due to insufficient
funding. For 23 patients evaluable for tumor responses, univariate
associations between genotypes and tumor response (PR and SD)
were evaluated using Fisher’s exact test. Overall survival (OS) and
progression free survival (PFS) were analyzed using Kaplan-Meier
models and associations between genotypes and patient survival
were assessed using log-rank tests. No sub-analyses were
performed for potential associations between genotypes and
toxicities since they were not pre-specified in our analysis plans.
All statistical analyses were performed using R package (version
3.0.2).

Potential associations between tumor response and
retrospectively analyzed genetic variations
For 21 patients, the retrospective analyses for additional
genotypes reported to be associated with treatment responses
were completed (the genotypic and allelic frequencies of the
interrogated variations are summarized in Table S2 in File S1). Of
note, the frequency of TSER*2 allele is higher in our current study
than those reported in the literature since the patients with the
TSER*3/*3 genotype were excluded in this study. When the two
additional loci in the TYMS genes (rs34743033 and rs34489327)
were assessed for their potential association with tumor response
(PR vs SD), the results did not indicate any statistically significant
association (Table 4). Among the five additional genotypes
analyzed, two genetic variations in the XRCC1 (c.1196G.A,
rs25487) and MDR1 (c.3435C.T, rs1045642) genes displayed a
trend supportive of their potential association with tumor response

Results
Patient characteristics
Patient baseline characteristics are listed in Table 1. Between
June 2008 and October 2010, 42 patients with gastric and GEJ
cancers were screened for their TSER genotypes; 26 patients
PLOS ONE | www.plosone.org
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Table 1. Baseline clinical and demographic characteristics of enrolled patients (n = 26).

Patients (n = 26)

Characteristic

No

%

TSER*2/*2

5

19

TSER*2/*3

21

81

Male

16

62

Female

10

38

TSER genotypes

Gender

Age (years)
median

56

range

26–81

Ethnicity
Caucasians

23

88

African Americans

2

8

Not reported

1

4

ECOG performance status
0

5

19

1

13

50

2

8

31

Gastric

19

73

Gastroesophageal junction (GEJ)

7

27

2

8

Primary tumor type

Prior neoadjuvant or adjuvant therapy (.6 months)
doi:10.1371/journal.pone.0107424.t001

small number of patients enrolled in the current study, therefore
necessitating further validation of this approach in a larger clinical
trial. It should be however noted that we observed a very
encouraging response rate of 83.3% in patients with the
homozygous TSER*2/*2 genotype (5 out of 6 patients experienced PR). This observation was from a very small number of
patients, but it suggests that the improvement in clinical outcomes
in patients with gastric and GEJ cancers may require selection of
patients with two TSER*2 alleles. Alternatively, the current
findings may be related to the presence of multiple molecular/
genetic factors contributing to chemotherapy response. Strategies
involving more than one host and tumoral markers will likely be
more successful in guiding therapeutic decision making. Currently
we cannot rule out the possibility that TSER genotypes may have
prognostic value, independent of therapy, in patients with gastric
and GEJ cancers as previously reported in patients with colorectal
cancer [37,38]. Consideration of the above-mentioned aspects will
be important in the design of future clinical trials which can
evaluate multifactorial treatment selection approaches in a larger
number of patients.
The findings from another prospective study with selection of
patients on the basis of TSER genotypes have been recently
reported in rectal cancer patients receiving neoadjuvant chemoradiation (n = 135) [21]. In this particular study, patients with good
risk TSER genotypes (at least one TSER*2 allele) were treated
with standard 5-FU-based chemoradiation. Patients with good risk
genotypes had higher rates of downstaging and pathologic
complete response than reported in unselected populations.
Patients with poor risk TSER genotypes (harboring no TSER*2
allele) were treated with irinotecan in addition to 5-FU-based

(p = 0.050 and 0.056, respectively, Fisher’s exact test, Table 4).
However, no apparent association was observed when OS and
PFS times were compared among the groups with differing
genotypes at the five loci (Table S3 in File S1).

Discussion
This clinical study is unique in that we for the first time applied
the strategy of prospectively assessing TSER genotypes to improve
clinical outcomes in gastric and GEJ cancers. Our initial
hypothesis was that selection of patients with good risk TSER
genotypes would improve the response rate for FOLFOX to 60%,
a 17% increase over the historic control response rate of 43%
observed in non-genotype selected patients. The observed
response rate in this study was 39.1% (9 PR out of 23 patients
evaluable for tumor response, 95% CI 22.2 to 59.2), not achieving
the primary study endpoint. The median OS and PFS times of
11.3 and 6.2 months in patients with good risk TSER genotypes
were also comparable to those reported in non-genotype selected
populations (Figure 2). Although the observed response rate did
not support the utility of TSER genotyping as a treatment
selection guide, it should also be noted that the enrolled patients
experienced a very promising disease control rate of 95.7% (9 PR
and 13 SD out of 23 patients), higher than those reported in the
literature [32–36]. The high disease control rate in the current
study may provide the first prospectively obtained evidence for the
utility of TSER genotyping in improving clinical outcomes in
patients with gastric and GEJ cancers.
The apparent lack of treatment outcome improvement in
patients with good risk TSER genotypes may be related to the

PLOS ONE | www.plosone.org
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12
3
8

Thrombocytopenia

Nausea

Vomiting

Diarrhea

5

2
8
10
5
10

Allergic reaction/hypersensitivity

Rash: hand-foot skin reaction

AST, SGOT

ALT, SGPT

Neuropathy: sensory

Fatigue (asthenia, lethargy, malaise)

doi:10.1371/journal.pone.0107424.t002

3
0

Vision-blurred vision

3

13

Anemia

8

3

Lymphopenia

Taste alteration (dysgeusia)

3

Mucositis/stomatitis

4

Neutropenia

40

20

40

32

8

0

12

32

12

32

12

48

36

52

12

12

16

1

4

2

2

0

1

0

0

1

0

3

2

3

6

4

2

5

No

No

%

Grade 2

Grade 1

Leukopenia (total WBC)

Toxicity

Table 2. Toxicities observed in the treated patients (n = 25).

4

16

8

8

0

4

0

0

4

0

12

8

12

24

16

8

20

%

2

2

0

1

0

0

0

0

0

0

1

1

0

1

1

4

4

No

Grade 3

8

8

0

4

0

0

0

0

0

0

4

4

0

4

4

16

16

%

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

4

0

No

Grade 4

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

16

0

%
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Table 3. Tumor responses to the FOLFOX regimen in patients of differing TSER genotypes.

Tumor response

TSER genotypes

P-valuea

TSER*2/*2

TSER*2/*3

(n = 6)

(n = 17)

No

%

No

%

PD (n = 1)

0

0

1

5.9

PR (n = 9)

5

83.3

4

23.5

SD (n = 13)

1

16.7

12

70.6

0.02

PD, progressive disease; PR, partial response; SD, stable disease.
a
Calculated using Fisher’s exact test for the association between response (PR and SD) and TSER genotype.
doi:10.1371/journal.pone.0107424.t003

chemoradiation. Patients in the poor risk groups receiving
additional therapies also showed higher rates of downstaging
and pathologic complete response than those for unselected
population. This study [21] however did not address whether

patients in the poor risk group would have had poorer clinical
outcomes if they had not received additional irinotecan therapy.
Nevertheless, these findings certainly support the utility of this
single genotype-based strategy in improving the clinical outcomes
of rectal cancer patients.

Figure 2. Kaplan-Meier curves showing overall survival (A) and
progression free survival (B) with 95% confidence intervals (CI)
in the patients enrolled.
doi:10.1371/journal.pone.0107424.g002

PLOS ONE | www.plosone.org

Figure 3. Kaplan-Meier curves showing overall survival (A) and
progression free survival (B) according to TSER genotypes.
doi:10.1371/journal.pone.0107424.g003
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Table 4. Univariate association between additional retrospectively analyzed genotypes and tumor response (PR: partial response
and SD: stable disease).

Gene

Tumor response

Genotype

PR (N = 9)

TYMS

TYMS

ERCC1

ERCC2

GSTP1

XRCC1

MDR1

P-valuea
SD (N = 11)

No.

%

No.

%

TSER*2/*2

5

56

1

9

TSER*2/*3(G)

2

22

4

36

TSER*2/*3(C)

2

22

6

55

+6 bp/+6 bp

5

56

6

55

+6 bp/26 bp

4

44

5

45

C/C

2

22

1

9

C/T

4

45

8

73

T/T

3

33

2

18

A/A

5

56

3

27

A/C

3

33

6

55

C/C

1

11

2

18

A/A

4

45

8

73

A/G

3

33

2

18

G/G

2

22

1

9

A/A

1

11

6

55

G/A

6

67

5

45

G/G

2

22

0

-

0

-

1

9

59-UTR TSER + G.C (rs34743033)

0.137

39-UTR 1494delTTAAAG(6 bp) (rs34489327)

1

c.354C.T (rs11615)

0.552

c.2251A.C (rs13181)

0.485

c.313A.G (rs1695)

0.552

c.1196G.A (rs25487)

0.050

c.3435C.T (rs1045642)
C/C
C/T

9

100

6

55

T/T

0

-

4

36

0.056

a

Calculated using Fisher’s exact test.
doi:10.1371/journal.pone.0107424.t004

arm (patients with the favorable TSER genotypes only) does not
allow us to gather treatment outcome for patients with the
unfavorable TSER genotypes. Our initial study design was indeed
two-armed (favorable vs. unfavorable TSER genotypes). But, the
reviewers in the NIH study section recommended that we revise
our study to be single armed for patients with favorable TSER
genotypes given the patient numbers and other resources
available. In future clinical trials, it would be certainly interesting
to prospectively compare treatment outcomes of patients with
favorable and unfavorable TSER genotypes.
Retrospective analyses for two additional TYMS genotypes
showed no significant association with tumor response (Table 4).
For additional non-TYMS genes analyzed, XRCC1 (c.1196G.A,
rs25487) and MDR1 (c.3435C.T, rs1045642) showed a potential
association to tumor response (Table 4). We performed these
analyses based on the previous findings on the potential association
between these genotypes and clinical outcomes in colorectal
cancer patients treated with FOLFOX [24,29,40]. However, we
did not observe any strong association between the tested
genotypes and tumor response, except a trend reflective of

No improvement in the overall response rate from this study
echo the inconsistent results observed in previous studies utilizing
TSER genotyping in treating patients with gastric and esophageal
cancers [6,39–41]. Less than expected response rates in our
current study as well as other previously reported retrospective
studies may be explained by the potential effect of oxaliplatin on
tumoral TS expression. The clinical synergy of combining 5-FU
with oxaliplatin is well documented and is key to the success and
frequent use of this combination regimen [42–44]. One proposed
explanation for this synergy is oxaliplatin-induced TS downregulation by as yet unexplained mechanisms [45,46]. If oxaliplatin
were to cause tumoral TS downregulation or any potential
molecular changes influencing tumor response, any benefits from
pretreatment TSER genotyping may have been obscured in our
current study. Interestingly, some in vitro studies also indicate that
irinotecan may also decrease TS activities and protein levels where
irinotecan could overcome 5-FU resistance in tumors [47,48].
These observations could help to explain the favorable response
results in the ‘‘poor risk’’ patients who received irinotecan in the
Tan et al. study [21]. However, our current study design of a single
PLOS ONE | www.plosone.org
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potential associations for XRCC1 and MDR1. Similar negative
results have been reported from retrospective analyses of TYMS
and non-TYMS genotypes in relation to the histopathological
tumor responses in patients with gastric and esophageal cancers
[39,41,49]. Interestingly, the polymorphisms in XRCC1 and
MDR1 have been associated with clinical outcomes in gastric
and colorectal cancer [24,50]. Further investigation in larger
clinical trials is warranted to determine whether our current
findings are indicative of varying impact of the tested genotypes in
different tumor types.
In summary, our strategy to improve response rates in patients
with gastric and GEJ cancers by pretreatment TSER genotyping
was unsuccessful, but even in the setting of some limitations of our
current study the high disease control rate was encouraging. The
future applicability of a single polymorphism strategy to guide
therapy selection, while feasible and attractive, does not appear to
yield results of sufficient impact to be generally applicable. Our
approach may aid in selecting patients who require chemotherapy
intensification to achieve favorable results by adding oxaliplatin or
irinotecan and avoid chemotherapy toxicities in those who may
have a favorable outcome with 5-FU alone. The contemporary
confluence of our capacity to molecularly target cancers and the
advancement of our ability to characterize patients and their
cancers using molecular genetics will allow for multiple variables
to be considered and applied towards improvements in cancer
care. TYMS polymorphism status does not appear to be a

singularly important treatment selection factor, but it may be a key
contributor to favorable outcomes in a multivariable genomically
based therapeutic approach.
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